title: [Fulminant acute hepatitis B after infliximab treatment in Crohn's disease].
authors.forename: Hellara
authors.initials: H
authors.lastname: Olfa
authors.forename: Gueddiche
authors.initials: G
authors.lastname: Aroua
authors.forename: Melki
authors.initials: M
authors.lastname: Wissem
authors.forename: Ben Mansour
authors.initials: BM
authors.lastname: Wafa
authors.forename: Loghmari
authors.initials: L
authors.lastname: Hichem
authors.forename: Ben Chaabène
authors.initials: BC
authors.lastname: Nabil
authors.forename: Bdioui
authors.initials: B
authors.lastname: Fethia
authors.forename: Safer
authors.initials: S
authors.lastname: Leila
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003424:Crohn Disease / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006509:Hepatitis B / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D000069285:Infliximab; D017114:Liver Failure, Acute / Q000821:virology*; D010949:Plasma
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D015415:Biomarkers; D005765:Gastrointestinal Agents; D000069285:Infliximab